ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

After Furlough, Blizzard, NCI Struggles to Clear Backlog and Resume Business

January 19, 1996

Oxaliplatin Added To 5-FU/LV Improves Disease-Free Survival In Early Colon Cancer

June 24, 2005

Orders Still Accepted For 20th Anniversary Special Publication

July 19, 1991

NCAB Asks Government To Take Steps Aimed at Reducing Health Hazards From Cigarettes

December 21, 1973

FASEB Calls For 15% Increase For NIH Next Fiscal Year.

January 26, 2001

Lung Cancer Clinical Trials Cost-Effective Alternative

October 31, 2003